Announces results from two Phase III trials of its investigational oral PCSK9 inhibitor, Enlicitide Decanoate
November 21, 2025
Source: drugdu
89
November 20 news, MerckMerck ( the trade name of Merck Inc., Rowe, New Jersey, USA) recently presented the results of its pivotal Phase III CORALreef Lipids and Phase III CORALreef HeFH trials for the first time at the American Heart Association (AHA) Scientific Sessions. The CORALreef Lipids trial evaluated the safety and efficacy of the investigational oral PCSK9 inhibitor enlicitide, administered once daily, in adults with a history of severe atherosclerotic cardiovascular disease (ASCVD) events or at risk of ASCVD who were already receiving stable lipid-lowering therapy or were intolerant to statins.
https://finance.eastmoney.com/a/202511203570023839.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
